NYSE:ZYME Zymeworks - ZYME Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.64 +0.57 (+7.06%) (As of 03/29/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.00▼$8.6750-Day Range$7.93▼$10.0052-Week Range$4.11▼$10.80Volume511,787 shsAverage Volume696,835 shsMarket Capitalization$553.31 millionP/E Ratio4.88Dividend YieldN/APrice Target$12.63 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zymeworks MarketRank™ ForecastAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside46.1% Upside$12.63 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.17Based on 8 Articles This WeekInsider TradingAcquiring Shares$16.07 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.03) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector211th out of 999 stocksPharmaceutical Preparations Industry84th out of 489 stocks 3.3 Analyst's Opinion Consensus RatingZymeworks has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.63, Zymeworks has a forecasted upside of 46.1% from its current price of $8.64.Amount of Analyst CoverageZymeworks has only been the subject of 4 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ZYME. Previous Next 0.0 Dividend Strength Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYME. Previous Next 2.1 News and Social Media Coverage News SentimentZymeworks has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Zymeworks this week, compared to 3 articles on an average week.Search Interest31 people have searched for ZYME on MarketBeat in the last 30 days. This is an increase of 82% compared to the previous 30 days.MarketBeat Follows6 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have bought 68,855.43% more of their company's stock than they have sold. Specifically, they have bought $16,073,510.00 in company stock and sold $23,310.00 in company stock.Percentage Held by InsidersOnly 1.63% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions88.28% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Zymeworks are expected to grow in the coming year, from ($2.03) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is 4.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is 4.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.20.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zymeworks (NYSE:ZYME) StockZymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.Read More Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Stock News HeadlinesMarch 9, 2023 | marketbeat.comZymeworks Offers Hope for More than Just Long-Term InvestorsZymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higherMarch 24, 2023 | americanbankingnews.comZymeworks (NYSE:ZYME) Trading Down 4.9%March 29, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 24, 2023 | americanbankingnews.comZymeworks (NYSE:ZYME) Earns "Overweight" Rating from Wells Fargo & CompanyMarch 23, 2023 | americanbankingnews.comHC Wainwright Weighs in on Zymeworks Inc.'s Q1 2023 Earnings (NYSE:ZYME)March 23, 2023 | americanbankingnews.comHC Wainwright Reiterates "Neutral" Rating for Zymeworks (NYSE:ZYME)February 21, 2023 | finance.yahoo.comZymeworks To Host Fourth Quarter And Full Year 2022 Results Conference CallFebruary 16, 2023 | stocknews.comThe 3 Hottest Biotech Stocks to Own in 2023 and 1 to AvoidMarch 29, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.January 4, 2023 | finance.yahoo.comZymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023December 14, 2022 | finance.yahoo.comZanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers SymposiumDecember 9, 2022 | finance.yahoo.comNew Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCSDecember 5, 2022 | finance.yahoo.comZymeworks to Transfer Stock Listing to NasdaqNovember 21, 2022 | finance.yahoo.comZymeworks Inc. (ZYME) Just Flashed Golden Cross Signal: Do You Buy?November 1, 2022 | finance.yahoo.comZymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 26, 2022 | seekingalpha.comZymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger MilestoneOctober 21, 2022 | finance.yahoo.comAnalyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage PipelineOctober 19, 2022 | benzinga.comZymeworks shares are trading higher after the company and Jazz Pharmaceuticals announced an exclusive license agreement to develop and commercialize zanidatamab. - Zymeworks (NYSE:ZYME) - BenzingaOctober 19, 2022 | investorplace.comWhy Is Zymeworks (ZYME) Stock Up Today? - InvestorPlaceOctober 19, 2022 | streetinsider.comForm 8-K Zymeworks Inc. For: Oct 18 - StreetInsider.comOctober 19, 2022 | nasdaq.comJazz Pharma To License Zymeworks' Zanidatamab For Total Potential Payments Of Up To $1.76 Bln - NasdaqOctober 19, 2022 | marketwatch.comZymeworks, Jazz agree to licensing deal for cancer drug - MarketWatchOctober 19, 2022 | finance.yahoo.comWhy Zymeworks Stock Is Soaring TodayOctober 19, 2022 | seekingalpha.comZymeworks stock surges 14% on license deal with Jazz for cancer drug zanidatamab - Seeking AlphaOctober 19, 2022 | marketwatch.comJazz Pharmaceuticals, Zymeworks in Zanidatamab License Pact - MarketWatchOctober 19, 2022 | businesswire.comZymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab - Business WireOctober 19, 2022 | finance.yahoo.comZymeworks, Jazz agree to licensing deal for cancer drugSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Company Calendar Last Earnings3/07/2023Today3/29/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A CIK1403752 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees455Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.63 High Stock Price Forecast$18.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+48.9%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$1.77 Trailing P/E Ratio4.79 Forward P/E RatioN/A P/E GrowthN/ANet Income$124.34 million Net Margins30.15% Pretax Margin-751.56% Return on Equity49.27% Return on Assets31.13% Debt Debt-to-Equity RatioN/A Current Ratio3.28 Quick Ratio3.28 Sales & Book Value Annual Sales$412.48 million Price / Sales1.32 Cash FlowN/A Price / Cash FlowN/A Book Value$5.35 per share Price / Book1.59Miscellaneous Outstanding Shares64,041,000Free Float62,997,000Market Cap$543.07 million OptionableOptionable Beta0.91 Key ExecutivesKen GalbraithChairman & Chief Executive OfficerNeil A. KlompasPresident & Chief Operating OfficerChristopher AstleChief Financial Officer & Senior Vice PresidentMark HollywoodEVP, Head-Technical & Manufacturing OperationsKaycia WildeVice President-Clinical OperationsKey CompetitorsProcaps GroupNASDAQ:PROCAvadel PharmaceuticalsNASDAQ:AVDLMorphoSysNASDAQ:MOREntrada TherapeuticsNASDAQ:TRDAAclaris TherapeuticsNASDAQ:ACRSView All CompetitorsInsiders & InstitutionsNeil A KlompasSold 2,977 sharesTotal: $23,309.91 ($7.83/share)Morgan StanleyBought 314,405 shares on 2/15/2023Ownership: 8.847%Millennium Management LLCSold 77,106 shares on 2/15/2023Ownership: 0.183%Susquehanna Fundamental Investments LLCBought 31,930 shares on 2/15/2023Ownership: 0.051%Man Group plcSold 142,256 shares on 2/15/2023Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions ZYME Stock - Frequently Asked Questions Should I buy or sell Zymeworks stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZYME shares. View ZYME analyst ratings or view top-rated stocks. What is Zymeworks' stock price forecast for 2023? 8 equities research analysts have issued 12-month price objectives for Zymeworks' stock. Their ZYME share price forecasts range from $8.00 to $18.00. On average, they expect the company's stock price to reach $12.63 in the next twelve months. This suggests a possible upside of 48.0% from the stock's current price. View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts. How have ZYME shares performed in 2023? Zymeworks' stock was trading at $7.86 at the beginning of 2023. Since then, ZYME stock has increased by 8.5% and is now trading at $8.53. View the best growth stocks for 2023 here. When is Zymeworks' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our ZYME earnings forecast. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) posted its quarterly earnings results on Tuesday, March, 7th. The company reported $4.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.62 by $0.03. The company had revenue of $402.49 million for the quarter, compared to the consensus estimate of $371.36 million. Zymeworks had a net margin of 30.15% and a trailing twelve-month return on equity of 49.27%. What ETFs hold Zymeworks' stock? ETFs with the largest weight of Zymeworks (NYSE:ZYME) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares Biotechnology ETF (IBB). What is Ali Tehrani's approval rating as Zymeworks' CEO? 9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA). When did Zymeworks IPO? (ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager. What is Zymeworks' stock symbol? Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME." Who are Zymeworks' major shareholders? Zymeworks' stock is owned by a variety of institutional and retail investors. Top institutional investors include EcoR1 Capital LLC (12.01%), Morgan Stanley (8.85%), Samsara BioCapital LLC (2.57%), Point72 Asset Management L.P. (1.19%), Sessa Capital IM L.P. (1.18%) and Granahan Investment Management LLC (1.17%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Diana Hausman, Ecor1 Capital, Llc, James Priour, Kathryn O'driscoll, Neil A Klompas and Neil Josephson. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zymeworks' stock price today? One share of ZYME stock can currently be purchased for approximately $8.53. How much money does Zymeworks make? Zymeworks (NYSE:ZYME) has a market capitalization of $546.27 million and generates $412.48 million in revenue each year. The company earns $124.34 million in net income (profit) each year or $1.77 on an earnings per share basis. How many employees does Zymeworks have? The company employs 455 workers across the globe. How can I contact Zymeworks? Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The official website for the company is www.zymeworks.com. The company can be reached via phone at (302) 274-8744, via email at ir@zymeworks.com, or via fax at 604-737-7077. This page (NYSE:ZYME) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.